Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Hedrin Dev 42 (also referred to as Hedrin 4% Lotion Dev 42) is an investigational, developmental formulation of dimeticone 4% lotion developed by Thornton & Ross. It is designed as an alternative dimeticone 4% formulation to the standard Hedrin 4% lotion, evaluated in a Phase III comparative clinical trial to determine whether it is more effective at preventing head louse egg hatching and eradicating head lice after two applications on days 0 and 7. As a physical, non-insecticidal pediculicidal agent, its active ingredient is dimeticone (a silicone polymer) which acts by physically coating and smothering head lice and their eggs, disrupting their osmotic balance rather than acting as a chemical neurotoxin. It is indicated for the treatment of head louse infestation (pediculosis capitis).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Hedrin Dev 42.